smurf1 inhibitor 1

Smurf1 inhibitor 1 is a inhibitor that promotes bone formation.

AC430 is a potent and specific small molecule inhibitor of janus kinase 2 (JAK2), which has been implicated as a target for therapy in both oncology and autoimmune disease. AC430 is currently being developed by Ambit. In preclinical studies, AC430 has exhibited potency against JAK2 and V617F mutated JAK2 in cell-based models that is at least equivalent to, and in most cases superior to, competing JAK2 inhibitors. In preclinical oncology and autoimmune models, AC430 is well tolerated and has significant efficacy at oral doses as low as 10 mg kg day.

Smurf1-IN-A01 (A01) 是泛素连接酶 Smad 泛素化调节因子-1(Smurf1)抑制剂，其kd=3.664 nM。它能够抑制 Smurf1 介导的 Smad1 5 降解，并提高 BMP-2 的反应性。

1-ethyl-6-fluoro-4-oxo-7-[4-(3-phenylpropanoyl)piperazin-1-yl]-1,4-dihydroquinoline-3-carboxylic acid 是一种用作分子结构单元的化合物，是一种SMURF1抑制剂。

SMURF1-IN-1是一种口服活性的特异性E3泛素蛋白连接酶1（SMURF1）选择性抑制剂，IC50值为92 nM。在大鼠肺部高压模型中显示出显著疗效，适用于肺动脉高压疾病的研究。